KEY TAKEAWAYS
- The study aimed to assess the efficacy and safety of trabectedin + pld in pts with platinum-sensitive relapsed OC in a real-world setting.
- Researchers observed that trabectedin with pld is effective and safe for elderly pts with relapsed ovarian cancer.
Trabectedin, in combination with pegylated liposomal doxorubicin (pld) is approved for the treatment of patients (pts) with platinum-sensitive relapsed ovarian cancer (OC). Nevertheless, there is currently limited information regarding this treatment in elderly pts with OC in a real-world setting.
María Jesús Rubio and the team aimed to evaluate the efficacy and safety of trabectedin in combination with pld (trabectedin + pld) in elderly pts (≥ 70 years old) with platinum-sensitive relapsed OC in a real-world setting.
Researchers designed an observational and multicentric study that would retrospectively evaluate trabectedin + pld in a real-world setting for the treatment of elderly pts diagnosed with platinum-sensitive relapsed OC, treated according to the summary of product characteristics (SmPC) from 15 GEICO-associated hospitals. Those pts ≥ 70 years old at the time of treatment initiation and platinum-free intervals ≥ 6 months were considered eligible.
About 43 pts (median age of 74.0 years) received treatment between January 1st, 2015, and December 31st, 2019, across 15 Spanish centers. Of these pts, 4 achieved a complete response (9.3%), 14 had a partial response (32.6%), and 13 experienced stable disease (30.2%) as their best radiological response.
In this analysis of biological overall response according to CA125 serum levels (using Rustin criteria), 14 pts responded to the treatment (32.6%), 11 pts responded and normalized (25.6%), 3 pts stabilized (7.0%), and three progressed (7.0%).
The median progression-free survival (PFS) and overall survival (OS) during the study were 7.7 months and 19.5 months, respectively. The most common grade 3/4 adverse events reported were neutropenia (n= 8, 18.7%) and asthenia (n= 5, 11.6%).
The study demonstrated that trabectedin + pld is a feasible and effective treatment in elderly pts with platinum-sensitive relapsed OC, advocating a tolerable safety profile, which is crucial in the palliative treatment of pts with OC.
The was funded by PharmaMar.
Source: https://pubmed.ncbi.nlm.nih.gov/38970024/
Rubio MJ, Manzano A, de Sande LM, et al. (2024). “Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study.” BMC Cancer. 2024 Jul 5;24(1):803. doi: 10.1186/s12885-024-12577-z. PMID: 38970024; PMCID: PMC11225319.
